The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
December 12, 2022
View Complete Issue         Table of Contents 2019 
Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) for Prostate Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) for Prostate Cancer (online only)
December 12, 2022 (Issue: 1665)
The FDA has approved lutetium lu 177 vipivotide tetraxetan (Pluvicto – Novartis) for treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adults previously treated...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) for Prostate Cancer (online only)
Article code: 1665e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.